Silverback Therapeutics (SPRY) Financials

ARS Pharmaceuticals, Inc. (SPRY) provides its financial statements to give investors and stakeholders insights into its financial performance. The income statement presents the company's revenue and expenses over a specific period. It shows the net income from stockholders, which indicates the profitability of the company.

One important financial metric is EBIT (earnings before interest and taxes), which represents the company's operating income before deducting interest and taxes. EBITDA (earnings before interest, taxes, depreciation, and amortization) is also a commonly used metric that provides a clearer picture of a company's profitability by excluding non-cash items such as depreciation and amortization.

Gross profit is another key measure that represents the revenue remaining after subtracting the cost of goods sold. It indicates the profitability of the company's core operations.

The balance sheet displays the company's financial position at a specific point in time, including its assets, liabilities, and stockholders' equity. Cash equivalents refer to highly liquid assets that can be easily converted into cash.

Net debt is calculated by subtracting a company's cash and cash equivalents from its total debt. It indicates the company's ability to meet its financial obligations.

Stockholders' equity represents the residual interest in the assets of the company after deducting liabilities. It reflects shareholders' ownership and indicates the company's net worth.

Total assets and total liabilities are crucial figures on the balance sheet. Total assets include all the resources owned by the company, while total liabilities represent the company's obligations.

Cash flow is a statement that shows the company's cash inflows and outflows during a specified period. It consists of three sections: operating cash flow, investing cash flow, and financing cash flow. These sections provide insights into how the company generates and uses its cash.

Free cash flow represents the cash generated from operations after deducting capital expenditures required to maintain or expand the company's asset base.

In summary, ARS Pharmaceuticals, Inc. (SPRY) releases financial statements to provide a comprehensive view of its financial performance, position, and cash flow.